Merck Eyes Emerging Biosimilars Market In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012